DICE · Dice Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.13M | - | - | $225.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $28.20M | $23.66M | - | $14.73M | $5.98M | $13.41M | - | $4.46M | - |
| SG&A | $11.30M | $7.91M | - | $6.44M | $2.32M | $5.45M | - | $4.44M | - |
| Total Operating Expenses | $39.50M | $31.57M | - | $21.17M | $21.74M | $8.09M | - | $16.13M | - |
| D&A | - | $244.0K | - | - | - | $180.0K | - | - | - |
| Operating Income | ($39.50M) | ($31.57M) | - | ($21.17M) | ($7.17M) | ($8.09M) | - | ($16.13M) | - |
| Interest Expense | - | - | - | $83.0K | $52.0K | $60.0K | - | $3.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($34.82M) | ($25.65M) | - | ($20.55M) | ($21.52M) | ($18.59M) | - | ($17.34M) | - |
| EPS - Basic | ($0.74) | ($0.54) | - | ($0.55) | ($3.27) | - | - | - | - |
| EPS - Diluted | ($0.74) | ($0.54) | - | ($0.55) | ($0.58) | - | - | - | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73.46M | $101.59M | $461.39M | $48.27M | $16.77M | $53.67M | $115.83M | $59.69M | - |
| Accounts Receivable | - | - | - | $1.50M | $1.50M | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.41M | $4.12M | $3.08M | $1.39M | $1.96M | $4.75M | $1.71M | $5.09M | - |
| Current Assets | $532.30M | $559.35M | $577.76M | $267.84M | $284.88M | $307.00M | $323.91M | $340.79M | - |
| Total Assets | $550.67M | $575.60M | $593.98M | $284.99M | $302.58M | $324.61M | $325.75M | $342.38M | - |
| Current Liabilities | $20.57M | $17.24M | $15.15M | $11.66M | $12.07M | $14.79M | $10.88M | $12.72M | - |
| Long-term Debt | - | - | - | - | - | $1.71M | $1.92M | $2.12M | - |
| Total Liabilities | $31.62M | $28.70M | $26.99M | $23.88M | $24.65M | $29.44M | $12.80M | $14.86M | - |
| Stockholders' Equity | $519.06M | $546.90M | $566.99M | $261.11M | $277.94M | $295.17M | $312.95M | $327.52M | ($29.62M) |
| Retained Earnings | ($248.06M) | ($213.24M) | ($187.59M) | ($164.37M) | ($143.82M) | ($122.30M) | ($103.71M) | ($87.51M) | - |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($22.44M) | - | - | - | ($14.16M) | - | - | - |
| Investing Cash Flow | - | ($337.65M) | - | - | - | ($24.45M) | - | - | - |
| Financing Cash Flow | - | $292.0K | - | - | - | ($108.0K) | - | - | - |
| CapEx | - | $202.0K | - | - | - | $365.0K | - | - | - |
| Free Cash Flow | - | ($22.64M) | - | - | - | ($14.53M) | - | - | - |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -637.7% | - | - | -7170.2% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | -1913.1% | - | - | -7704.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 0.88 | - | - | - | 0.78 | - | - | - |
| R&D / Revenue | - | - | - | - | 531.7% | - | - | 1980.9% | - |
| SG&A / Revenue | - | - | - | - | 206.0% | - | - | 1975.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.3% | -4.5% | - | -7.2% | -7.1% | -5.7% | - | -5.1% | - |
| Return on equity | -6.7% | -4.7% | - | -7.9% | -7.7% | -6.3% | - | -5.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 25.88 | 32.44 | 38.14 | 22.96 | 23.61 | 20.75 | 29.77 | 26.79 | - |
| Quick ratio | 25.88 | 32.44 | 38.14 | 22.96 | 23.61 | 20.75 | 29.77 | 26.79 | - |
| Cash ratio | 3.57 | 5.89 | 30.46 | 4.14 | 1.39 | 3.63 | 10.64 | 4.69 | - |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | 0.01 | 0.01 | 0.01 | - |
| Debt / Assets | - | - | - | - | - | 0.01 | 0.01 | 0.01 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -255.0x | -138.0x | -134.8x | - | -5377.7x | - |
| Equity multiplier | 1.06 | 1.05 | 1.05 | 1.09 | 1.09 | 1.10 | 1.04 | 1.05 | - |
| Liabilities / Assets | 0.06 | 0.05 | 0.05 | 0.08 | 0.08 | 0.09 | 0.04 | 0.04 | - |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | 0.00 | - | - | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 487d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -450.6% | -290.5% | - | -31.2% | - | - | - | - | - |
| Net income growth (YoY) | -61.8% | -37.9% | - | -18.5% | - | - | - | - | - |
| EPS growth (YoY) | -27.6% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -55.8% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 86.8% | 85.3% | 81.2% | -20.3% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing DICE Therapeutics against the 5 most active filers in the same SIC group.